Eisai R&d Management Co., Ltd.

Eisai Company, Limited

Eisai Inc.

Xiang-Yi Li

John JianShi Wang

Yimin Jiang

Bruce Decosta

Mark Spyvee

Kenzo Muramoto

Hong Du

Fabian Gusovsky

John (Yuan) Wang

Sergei I Agoulnik

Toshihiko Kaneko

Jean-Christophe P Harmange

Seiichi Kobayashi

Kouichi Kikuchi

Motohiro Soejima

Ieharu Hishinuma

Boris M Seletsky

Heather Davis

Wanjun Zheng

André Lescarbeau

Huiming Zhang

Norihito Ohi

Hiromitsu Yokohama

Kenichi Nomoto

Marc Pesant

Ye Yao

Lynda Tremblay

Yan (Janet) Zhao

Jane Daun

Satoshi Yamamoto

Roch Boivin

Naoki Yoneda

Tomohiro Matsushima

Atsushi Inoue

Makoto Kotake

Yoshiyuki Kawakami

Kenichi Chiba

Hiroshi Shirota

Yoshiharu Mizui

Isao Tanaka

Masaki Goto

Yoshikazu Kuboi

Yoshihito Eguchi

Hideki Sakurai

Masanori Fujita

Jesse Chow

Akifumi Kimura

Jiayi Wu

Takatoshi Kawai

Charles-André Lemelin

Megumi Kawada

Yong-Chun Shen

John (yuan) Wang

Lynn D Hawkins

Shawn Schiller

Frank Fang

Charles W Johannes

Pamela McGuiness

Mary Vermeulen

Kozo Akasaka

Erin A Murphy

John Wang

The present invention provides compounds, pharmaceutical compositions and methods for the treatment of specific cancers. Such compositions may generally comprise a compound of formula (I): wherein R-Rare as defined herein, or pharmaceutically acceptable salts or esters thereof; and a pharmaceutically acceptable carrier.

Multikinase inhibitors for use in the treatment of cancer

The present invention provides compounds, pharmaceutical compositions and methods for the treatment of specific cancers. Such compositions may generally comprise a compound of formula (I): 

The present invention provides compounds having formula (I): 

Deazapurines and uses thereof

The present invention provides methods for the use of compounds having formula (I) in the treatment of various disorders including inflammatory or autoimmune disorders, and disorders involving malignancy or increased angiogenesis, wherein R-R, t, X, Y, Z, and n are as defined herein.

Macrocyclic compounds useful as pharmaceuticals

As discussed above, there remains a need for the development of novel therapeutic agents useful for treating inflammatory or autoimmune and proliferative diseases. The present invention provides novel compounds of general formula (I), and pharmaceutical compositions thereof, as described generally and in classes and subclasses herein, as well as methods of making and using such compounds.

The present invention provides compounds having formula (1): wherein R-R, A, J, D, E, G, Q, w, x, y, and z are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof in the treatment of cancer and/or inflammatory disorders, and more generally as proteasome inhibitors.

Eponemycin and epoxomicin analogs and uses thereof

The present invention provides compounds having formula (I), wherein R, R, Rand n are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof in the treatment of inflammatory or autoimmune and proliferative disorders and as inhibitors of cell adhesion molecule expression and inflammatory cytokine signal transduction generally 

Growing community of inventors

Andover, MA, United States of America

Xiang-Yi Li